Loading
Routine Observational / Icotinib / NSCLC (non Small Cell Lung Cancer) · Observational Study
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a multicenter retrospective observational registry record for a study of adjuvant icotinib in EGFR-mutant stage IA2–IB NSCLC that is currently recruiting; no results are posted in this registry entry. The planned analysis will use propensity score matching to compare overall survival between patients who received icotinib and those who received routine follow-up.
Observational. NSCLC (Non-small Cell Lung Cancer); age from 18 Years. Intervention: Icotinib Group; Routine Observational Group. Compared with: Routine observational follow-up after surgery. n = 2,572. 2 sites: China.
This is a multicenter retrospective observational registry record for a study of adjuvant icotinib in EGFR-mutant stage IA2–IB NSCLC that is currently recruiting; no results are posted in this registry entry. The planned analysis will use propensity score matching to compare overall survival between patients who received icotinib and those who received routine follow-up.
No safety data, event rates, hazard ratios, confidence intervals, or p-values are provided in this registry record.
The source did not state who this applies to in practice.
This is a registry record for a recruiting observational study with no results posted; it describes planned conduct and endpoints only, not evidence of efficacy or safety.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07806604). This is a study registration, not published results. Lead sponsor: Betta Pharmaceuticals Co., Ltd.. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 2572 participants (ESTIMATED). Conditions: NSCLC (Non-small Cell Lung Cancer). Interventions: DRUG: Icotinib; OTHER: Routine Observational. Primary outcome measures: Overall survival period（OS） , Data collection deadline (This study is a retrospective study and there is no predetermined evaluation time).The index date for this study is defined as 4 weeks following complete surgical resection (R0).. Brief summary: This is a multicenter, retrospective, observational real-world study designed based on real-world data. Eligible medical institutions that meet standardized data quality requirements and have an adequate sample size will be enrolled in this study. The treatment group consists of patients with completely resected (R0) stage IA2 high-risk to IB non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations who received adjuvant icotinib therapy after radical resection. The control group includes patients with completely resected (R0) stage IA2 high-risk to IB NSCLC with positive EGFR-sensitizing mutations who received routine observational follow-up after surgery. Propensity score-matched analyses will be conducted between the treatment and control groups to evaluate the efficacy and safety of adjuvant icotinib therapy in this patient population.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.